Affiliation:
1. Department of Medical Laboratory Sciences College of Medicine and Health Sciences, Wollo University Dessie Ethiopia
2. Department of Medical Biochemistry School of Medicine, College of Health Sciences, AAU Addis Ababa Ethiopia
Abstract
AbstractBackgroundGastric cancer (GC), a malignant epithelial tumor, is the fourth leading cause of cancer‐related death worldwide. Therapeutic strategies for GC, despite the biggest challenges, can significantly improve survival rates through early detection and effective screening methods.AimTo provide brief information on the necessity of multiple specific diagnostic, prognostic, and predictive markers for GC.MethodsThis review was conducted using a variety of search engines, including PubMed Central, Scopus, Web of Science, Google Scholar, and others.ResultsSome potential biomarkers that provide essential information include circulating tumor cells (CTCs), DNA methylation, claudin 18.2, fibroblast growth factor receptor 2 (FGFR2), long noncoding RNAs (lncRNAs), cell‐free DNA (cfDNA), microRNAs, and serum pepsinogens.ConclusionMultiple tumor markers are essential for screening, tumor identification, staging, prognostic assessment, and monitoring recurrence after therapy due to the absence of a single tumor indicator for diagnosing, prognosticating, and predicting GC.
Reference156 articles.
1. Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer;Perrot‐Applanat M;Oncol Lett,2019
2. Treatment of gastric cancer
3. Epidemiology of stomach cancer
4. Iron deficiency accelerates Helicobacter pylori–induced carcinogenesis in rodents and humans
5. Global burden of gastric cancer attributable toHelicobacterpylori